JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr

India Formulation sales accounted for 34.2% of total consolidated sales for the quarter

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025

Ajanta Pharma reports Q1 FY26 consolidated PAT at Rs. 255.34 Cr

Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025

Vijaya Diagnostic reports Q1 FY26 consolidated PAT at Rs. 38.33 Cr

The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal

Torrent Pharmaceuticals posts Q1 FY26 consolidated PAT higher at Rs. 548 Cr

Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025

UK journal publishes complex case of severe pan-drug resistant infection in US liver transplant patient successfully treated with Zaynich

This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins

Laurus Labs consolidated Q1 FY2026 PAT at Rs. 163.02 Cr

Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025

Solara Active Pharma Sciences consolidated Q1FY26 PAT rises to Rs. 10.52 Cr

Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025

RPG Life Sciences Q1 FY2026 PAT slips to Rs. 26.29 Cr

RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025